Pre-earnings options volume in Reviva Pharmaceuticals (RVPH) Holdings is normal with calls leading puts 25:1. Implied volatility suggests the market is anticipating a move near 21.1%, or 0c, after results are released. Median move over the past eight quarters is 7.2%.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Largest borrow rate increases among liquid names
- Reviva Pharmaceuticals announces grant of European patent for brilaroxazine
- Reviva Pharmaceuticals’ Brilaroxazine Study: A Potential Game-Changer in Schizophrenia Treatment
- Reviva Pharmaceuticals price target lowered to $4 from $11 at H.C. Wainwright
- Unusually active option classes on open October 23rd